Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of KH-001 Besylate in Healthy Males
NCT07868237Phase 1Completed
- Sponsor
- Kadence Bio
- Start
- Nov 2023
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KH-001 in premature ejaculation (PE) (3 arms), sponsored by Kadence Bio. Primary endpoints: Treatment-Emergent Adverse Events at Day 12, Clinically Significant Abnormal Clinical Laboratory Values at Day 12 and 2 more. Started Nov 2023; status: completed.
02
Drugs
KH-001
03
Conditions
premature ejaculation (PE)
Beyond the preview
Go deeper on NCT07868237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07868237.